US20050107470A1 - Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia - Google Patents

Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia Download PDF

Info

Publication number
US20050107470A1
US20050107470A1 US10/510,450 US51045005A US2005107470A1 US 20050107470 A1 US20050107470 A1 US 20050107470A1 US 51045005 A US51045005 A US 51045005A US 2005107470 A1 US2005107470 A1 US 2005107470A1
Authority
US
United States
Prior art keywords
carnitine
acetyl
propionyl
use according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/510,450
Other languages
English (en)
Inventor
Giorgio Cavillini
Giulio Biagiotti
Aleardo Koverech
Francesca Sardelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Assigned to SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. reassignment SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIAGIOTTI, GIULIO, CAVALLINI, GIORGIO, KOVERECH, ALEARDO, SARDELLI, FRANCESCA
Publication of US20050107470A1 publication Critical patent/US20050107470A1/en
Priority to US12/230,992 priority Critical patent/US8415392B2/en
Assigned to ALFASIGMA S.P.A. reassignment ALFASIGMA S.P.A. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Definitions

  • the invention described herein relates to the use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine, in combination, for the preparation of a medicine for the treatment of oligoasthenoteratospermia of any origin: inflammatory, idiopathic, hormonal, or associated with varicocele.
  • vitamin E glutathione, NADH
  • transmediastinic testicular artery has a significantly greater resistivity index in non-obstructive azoospermic subjects than in controls and in oligoasthenospermic subjects.
  • the spermatozoa are produced in the testicles and undergo post-gonadal maturation in the epididymis in order to acquire their fertilising capacity.
  • high-molecular-weight proteins and small molecules such as the free carnitines facilitate the maturation of the gametes into competent, functional cells.
  • Epididymal L-carnitine which comes from the plasma, has a beneficial effect on the spermatozoa. It passes into the spermatozoa by passive diffusion and is acetylated only in mature spermatozoa.
  • L-carnitine acetyl L-carnitine and propionyl L-carnitine in combination is already known.
  • a dietetic composition consisting of L-carnitine, acetyl L-carnitine and propionyl L-carnitine, which is useful for athletes subject to intense physical effort, or for asthenic individuals.
  • a dietetic composition consisting of L-carnitine, acetyl L-carnitine and propionyl L-carnitine for the treatment of alcohol withdrawal syndrome.
  • L-carnitine and of the alkanoyl L-carnitines for the treatment of male infertility.
  • compositions useful for the treatment of oligoasthenoteratospermia which do not present the disadvantages of the above-mentioned known compounds, or which improve the results obtained with the best of the known compositions currently in use.
  • One object of the present invention therefore is the use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts or their pharmaceutically acceptable salts for the preparation of a medicine for the treatment of oligoasthenoteratospermia.
  • a further object of the present invention is the use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts or their pharmaceutically acceptable salts, for the preparation of a medicine for the treatment of oligospermia.
  • a further object of the present invention is the use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts or their pharmaceutically acceptable salts, for the preparation of a medicine for the treatment of asthenospermia.
  • a further object of the present invention is the use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts or their pharmaceutically acceptable salts, for the preparation of a medicine for the treatment of teratospermia.
  • a further object of the present invention is the use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine or their pharmaceutically acceptable salts, for the preparation of a nutritional composition for the treatment of oligoasthenoteratospermia.
  • a further object of the present invention is the use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine or their pharmaceutically acceptable salts, for the preparation of a nutritional composition for the treatment of oligospermia.
  • a further object of the present invention is the use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine or their pharmaceutically acceptable salts, for the preparation of a nutritional composition for the treatment of asthenospermia.
  • a further object of the present invention is the use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine or their pharmaceutically acceptable salts, for the preparation of a nutritional composition for the treatment of teratospermia.
  • the combination according to the present invention is more active than the combination of L-carnitine and acetyl L-carnitine mentioned above, in improving both sperm count and sperm motility in man.
  • L-carnitine, acetyl L-carnitine and propionyl L-carnitine can be in any form suitable for oral or parenteral administration in man.
  • L-carnitine, acetyl L-carnitine and propionyl L-carnitine can be formulated together, as a mixture, or can be formulated separately (packaged separately), using known methods.
  • L-carnitine, acetyl L-carnitine and propionyl L-carnitine can be administered to an individual either when fomulated in a mixture or when formulated in separate packs.
  • the combination according to the present invention can be marketed as a health food supplement, a nutritional supplement, or as a therapeutic product on sale with or without the need for a medical prescription.
  • the molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of one of their pharmaceutically acceptable salts ranges from 2.48:0.098:0.092 to 0.186:0.98:0.92.
  • Alternative molar ratios include the molar ratios ranging from 2.48:0.49:0.46 to 0.62:0.49:0.46.
  • Alternative molar ratios include the molar ratios ranging from 2.48:0.98:0.92 to 1.24:0.49:0.23.
  • the combination preparation according to the present invention when in unit dosage form, contains from 4.0 g to 0.30 g of L-carnitine inner salt, from 0.20 to 2.0 g of acetyl L-carnitine inner salt and from 0.20 g to 2.0 g of propionyl L-carnitine inner salt, or an equimolar amount of one of their pharmaceutically acceptable salts.
  • the preferred combination preparation in unit dosage form, contains 2 g of L-carnitine inner salt, 1 g of acetyl L-carnitine inner salt and 0.5 g of propionyl L-carnitine inner salt, or an equimolar amount of one of their pharmaceutically-acceptable salts.
  • Inclusion criteria young infertile males with astheno-zoospermia recognised as being the sole cause of infertility over the preceding period of at least two years; the semen criteria that had to be fulfilled in at least two samples were: sperm concentration (M/ml) from 10 to 20, motility (%) >20 ⁇ 40 at 2 hours, rapid linear progression (%) ⁇ 20 at 2 hours.
  • the patients were subjected to history taking, bilateral scrotal echo-colour Doppler, physical examination, hormone assays (free and total testosterone, FSH, LH, 17 beta oestradiol, progesterone, prolactin), and a spermiogram (WHO 1999).
  • Exclusion criteria acute genital inflammation, sperm concentration ⁇ 5,000,000/ml. All patients gave their informed consent for participation in this open trial. In all, the patients examined were 8 patients with varicocele (6 grade II, 2 grade III), 12 parients with chronic inflammation of the sex glands, 12 patients with varicocele (8 grade II, 4 grade III)+chronic inflammation of the sex glands, 25 with cryptogenetic oligoasthenospermia, 2 with hypogonadotropic hypogonadism, 1 with hyperprolactinaemia, 4 with a history of surgery (unilateral cryptorchidia in 3 cases, bilateral in 1 case) and 2 with bilateral testicular trauma.
  • Semen was obtained by masturbation after at least 4 days of sexual abstinence. Semen samples were analysed within one hour of ejaculation for all parameters, using the standard methods recommended by the WHO (1987). Sperm motility was studied using a computerised motility analyser on at least two samples.
  • L-carnitine was administered at the dose of 2 g/day (2 ⁇ 500 mg tablets twice daily, after lunch) for 4 months; acetyl L-carnitine was administered at the dose of 1 g/day for 4 months, while propionyl L-carnitine was administered at the dose of 500 mg/day for 4 months.
  • the combination according to the present invention significantly increases the sperm concentration and motility as well as the percentage of spermatozoa with a rapid linear progression as compared to treatment with the L-carnitine plus acetyl L-carnitine combination, regardless of the cause of the oligoasthenoterato-spermia, even in patients with hormonal abnormalities.
  • the combination according to the invention has permitted a reduction in the posology of gonadotropins and antiprolactinaemia drugs compared to the data reported in the literature.
  • the medicine according to the invention described herein can be prepared by mixing the active ingredients (L-carnitine inner salt, acetyl L-carnitine inner salt and propionyl L-carnitine inner salt or one of their pharmacologically acceptable salts) with suitable excipients for the fomulation of compositions for enteral (particularly oral) or parenteral (particularly intramuscular of intravenous) administration. Experts in pharmaceutical technology are familiar with said excipients.
  • the pharmaceutically acceptable salts of the above-mentioned active ingredients include all the pharmaceutically acceptable salts that are prepared by addition of an acid to the L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salt, and that do not give rise to unwanted toxic or side effects.
  • the formation of salts by addition of an acid is well known in pharmaceutical technology.
  • salts are: chloride, bromide, orotate, aspartate, acid aspartate, citrate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate, acid fumarate, magnesium fumarate, glycerophosphate, lactate, maleate and acid maleate, mucate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-amino ethane sulphonate, magnesium 2-amino ethane sulphonate, methane sulphonate, choline tartrate, trichloroacetate and trifluoroacetate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US10/510,450 2002-04-09 2003-04-08 Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia Abandoned US20050107470A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/230,992 US8415392B2 (en) 2002-04-09 2008-09-09 Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002RM000194A ITRM20020194A1 (it) 2002-04-09 2002-04-09 Composizione utile per aumentare la concentrazione e la motilita' degli spermatozoi e migliorarne la morfologia nell'uomo.
ITRM2002A000194 2002-04-09
PCT/IT2003/000214 WO2003084526A1 (en) 2002-04-09 2003-04-08 Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/230,992 Division US8415392B2 (en) 2002-04-09 2008-09-09 Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia

Publications (1)

Publication Number Publication Date
US20050107470A1 true US20050107470A1 (en) 2005-05-19

Family

ID=11456235

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/510,450 Abandoned US20050107470A1 (en) 2002-04-09 2003-04-08 Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia
US12/230,992 Expired - Lifetime US8415392B2 (en) 2002-04-09 2008-09-09 Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/230,992 Expired - Lifetime US8415392B2 (en) 2002-04-09 2008-09-09 Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia

Country Status (20)

Country Link
US (2) US20050107470A1 (de)
EP (1) EP1492521B1 (de)
JP (1) JP4663987B2 (de)
KR (1) KR20040098005A (de)
CN (1) CN1330301C (de)
AT (1) ATE476974T1 (de)
AU (1) AU2003224443B2 (de)
BR (1) BR0309055A (de)
CA (1) CA2478674C (de)
CY (1) CY1111273T1 (de)
DE (1) DE60333742D1 (de)
DK (1) DK1492521T3 (de)
ES (1) ES2350338T3 (de)
HK (1) HK1078460A1 (de)
IT (1) ITRM20020194A1 (de)
MX (1) MXPA04009763A (de)
PL (1) PL214859B1 (de)
PT (1) PT1492521E (de)
SI (1) SI1492521T1 (de)
WO (1) WO2003084526A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
US20130136802A1 (en) * 2009-05-01 2013-05-30 Parviz Gharagozloo Treating male infertility secondary to sperm oxidative stress

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776913B2 (en) 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause
CN108041588A (zh) * 2017-12-08 2018-05-18 冯纪敏 一种含有海藻糖的组合物及其应用
CN109999042B (zh) * 2019-05-16 2021-05-18 北京华睿鼎信科技有限公司 包含脱氢表雄酮或其硫酸酯、左卡尼汀、乙酰左卡尼汀或它们的可药用盐的组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255346B1 (en) * 1997-10-03 2001-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1249462B (it) * 1991-10-21 1995-02-23 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e acil l-carnitine nel trattamento delle oligoastenospermie idiopatiche.
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
GB9721746D0 (en) 1997-10-15 1997-12-10 Panos Therapeutics Limited Compositions
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
ITRM20010029A1 (it) * 2001-01-23 2002-07-23 Aldo Fassi Sali metallici di carnitine utili come integratori dietetici/nutrizionali o come farmaci, composizioni che li contengono e procedimenti per
ITRM20020055A1 (it) 2002-02-04 2003-08-04 Aldo Fassi Sali metallici di carnitine, integratori dietetici/nutritivi che li contengono e kit dietetici per contrastare disturbi sessuali in soggetti

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255346B1 (en) * 1997-10-03 2001-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130136802A1 (en) * 2009-05-01 2013-05-30 Parviz Gharagozloo Treating male infertility secondary to sperm oxidative stress
US9943543B2 (en) * 2009-05-01 2018-04-17 Parviz Gharagozloo Treating male infertility secondary to sperm oxidative stress
US20220008460A1 (en) * 2009-05-01 2022-01-13 Parviz Gharagozloo Treating male infertility secondary to sperm oxidative stress
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors

Also Published As

Publication number Publication date
HK1078460A1 (en) 2006-03-17
PT1492521E (pt) 2010-11-11
CA2478674A1 (en) 2003-10-16
CN1638754A (zh) 2005-07-13
CY1111273T1 (el) 2015-08-05
KR20040098005A (ko) 2004-11-18
MXPA04009763A (es) 2004-12-13
CA2478674C (en) 2010-10-19
JP2006505499A (ja) 2006-02-16
ATE476974T1 (de) 2010-08-15
ITRM20020194A0 (it) 2002-04-09
JP4663987B2 (ja) 2011-04-06
EP1492521A1 (de) 2005-01-05
US8415392B2 (en) 2013-04-09
PL214859B1 (pl) 2013-09-30
DE60333742D1 (de) 2010-09-23
EP1492521B1 (de) 2010-08-11
DK1492521T3 (da) 2010-11-22
US20090012169A1 (en) 2009-01-08
AU2003224443A1 (en) 2003-10-20
ITRM20020194A1 (it) 2003-10-09
PL372924A1 (en) 2005-08-08
ES2350338T3 (es) 2011-01-21
SI1492521T1 (sl) 2010-12-31
CN1330301C (zh) 2007-08-08
AU2003224443B2 (en) 2008-09-11
BR0309055A (pt) 2005-02-22
WO2003084526A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
US8415392B2 (en) Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia
CA2314942C (en) Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
CN105792818B (zh) 用于促进女性生育力的组合物
EP0630181A1 (de) Ernährungsprodukt für verletzte und chirurgische patienten
JP2005505500A (ja) 無月経及び関連疾患を治療するためのタンパク質及び必須アミノ酸の使用
US5863940A (en) Medicament and therapeutical method for treating idiopathic asthenozoospermia
KR20180137605A (ko) 남성 불임을 치료하기 위한 ｄ－아스파르트산 및 ｌ－아스파르트산 또는 이들 염의 조합체의 용도
EP1569635B1 (de) Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
WO2003066573A1 (en) Metal salts of carnitines, dietary supplements containing same and dietary kits for counteracing sexual disorders in male subjects
MXPA00005352A (en) Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
Lagua AA. Abbreviation for 1. Adenylic acid. 2. Amino acid. 3. Alcoholics Anonymous. AAA. Abbreviation for aromatic amino acid. ABeD. Abbreviation for Advocates for
ITMI981037A1 (it) Uso di l-aspartato di potassio e di magnesio per aumentare la concentrazione ematica di glutammina

Legal Events

Date Code Title Description
AS Assignment

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAVALLINI, GIORGIO;BIAGIOTTI, GIULIO;KOVERECH, ALEARDO;AND OTHERS;REEL/FRAME:016185/0223

Effective date: 20040911

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ALFASIGMA S.P.A., ITALY

Free format text: MERGER;ASSIGNOR:SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.;REEL/FRAME:044760/0906

Effective date: 20170801